19 Feb GenXys Health Care Systems announces completion of oversubscribed seed round financing to launch leading precision prescribing software into the US market
GenXys, a precision prescribing software company tackling a $130 billion global problem, is pleased to announce that it has closed its oversubscribed seed round at $1.77 million, with key investors TYDO and TELUS Ventures. Following early commercial success in Canada, this financing supports GenXys plans to expand into new regions to increase patient safety and medication effectiveness whilst reducing healthcare costs with its market-leading precision prescribing software solution.
Vancouver, Canada, January 2019. In response to increased demand for its precision prescribing solutions, GenXys Health Care Systems Inc., the Canadian-based precision prescribing software company, is embarking on launch plans into the USA while continuing to build and support its Canadian business with key strategic partners. “We have a crystal-clear vision that every prescription, globally, will be powered by our software. Our capital partners support our mission of enabling society to benefit from truly personalized medications, to replace the current trial and error approach to prescribing” said GenXys CEO Karl Pringle.
GenXys’ TreatGx software, capable of identifying optimal drug options for patients, helps employers and benefit providers reduce health absenteeism costs while improving productivity. Incorporating biophysical, drug, disease, and pharmacogenetic data, the software identifies optimal therapeutic options for the individual. Healthcare networks including executive health organizations currently utilize the GenXys solutions to improve patient safety, treatment efficacy while reducing costs.
“By considering thousands of pieces of information using advanced computational analysis, our unique precision prescribing software helps find the right drug options, tailored precisely for each person, within seconds,” said Professor Martin Dawes, GenXys Founder, and CSO. GenXys has embarked on a number of ground-breaking initiatives to consolidate and enhance its market-leading position as it enters the US market. Dr. Mark Gelfer, Chairman of the Board is delighted; “having the breadth of local capital partners with strategic relationships and representation on our Board will help GenXys achieve its vision”.
GenXys, with global headquarters in Vancouver Canada, provides the world’s most comprehensive precision prescribing solutions to solve healthcare’s most pressing challenges. TreatGx, the precision prescribing software with pharmacogenetics prevents inappropriate prescribing and adverse drug reactions, a leading cause of death, and personalize drug selection to increase drug efficacy. Powering every prescription globally with their software improves medication safety, increases drug effectiveness and reduces healthcare costs.
To learn more about GenXys visit www.genxys.com
Email: email@example.com / firstname.lastname@example.org
Market Watch: TELUS Ventures announces new equity investments in Canadian Precision Medicine and Diagnostics companies
BetaKit: Drug prescription healthtech, GenXys, closes $1.77 million seed round
Telecompaper: Telus Ventures announces new equity investments in medicine start-ups
Genome Web: GenXys Closes $1.4M Seed Financing Round
e@UBC:GenXys Health Care Systems announces completion of oversubscribed seed round